SLC5A2 and metabolic dysfunction-associated steatotic liver disease: A meta-analysis of SGLT2 inhibitors in NAFLD evidenced a significant reduction in aspartate aminotransferase (AST), alanine aminotransferase (ALT), liver fibrosis and visceral fat [189].